“A lot of people have H. pylori, but very few have bad outcomes. Is that due to the organism or the host?” says Martin Blaser, a microbiologist at New York University School of Medicine. “This paper provides evidence that the fit is important. It’s a very nice advance.”

The study led by Pelayo Correa and Scott Williams at Vanderbilt University Medical Center in Nashville, Tennessee, has shown that this mismatch can turn a normally benign infection into a potentially carcinogenic one. When analysed together, the genomes of hosts and microbes give a better prediction of the risk of disease than when considered alone, the team found. Their results were published in Proceedings of the National Academy of Sciences.

For original article, please see:http://www.nature.com/news/human-microbe-mismatch-boosts-risk-of-stomach-cancer-1.14501.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com